PMID: 3743903Jan 1, 1986Paper

Biologicals and vaccines: regulatory perspectives

Developments in Biological Standardization
J C Petricciani

Abstract

The new biotechnology has opened the door to a very broad array of new pharmaceutical products which lend themselves to high degrees of purity and potency. From a regulatory point of view, the two basic questions of safety and efficacy are central to their approval for marketing. The kinds of safety tests which should be done on these new products will be discussed, as will the novel safety issues related to the use of abnormal mammalian cells as substrates for the production of some new drugs and biologicals. In addition, the relative need for efficacy studies will be discussed in the context of a genetically engineered product when the "natural" product has already been shown to be effective and is commercially available.

Related Concepts

Related Feeds

Bioinformatics in Biomedicine

Bioinformatics in biomedicine incorporates computer science, biology, chemistry, medicine, mathematics and statistics. Discover the latest research on bioinformatics in biomedicine here.

Related Papers

Developments in Biological Standardization
J C Petricciani
JAMA : the Journal of the American Medical Association
Thijs J GiezenAntoine C G Egberts
Biologicals : Journal of the International Association of Biological Standardization
D J WoodElwyn Griffiths
Developments in Biological Standardization
M S SethiB S Samagh
© 2021 Meta ULC. All rights reserved